AMYT.L Regulatory News (AMYT)

9 October 2017

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Result of General Meeting and Completion of Placing

Amryt, the biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that all resolutions proposed at the Company's General Meeting, held today, were duly approved by shareholders.

As a result, shareholders have granted the Company's directors the authority to allot and issue, and the Company's directors have resolved to allot and issue, 66,477,651 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").

Unless the context otherwise requires, defined terms shall have the meaning ascribed to them in the Circular. The Circular is available on the Company's website www.amrytpharma.com/.

 Director Dealings

Certain of the Company's Directors have participated in the Placing on the same terms as other investors. The level of such participation, as well as each Director's interests in the Company's issued share capital before and following completion of the Placing are set out below.

Notes:

*Mr Ziener is the Executive Managing Director and board representative for Software AG Stiftung, which holds 22.3% of the Company's issued share capital following the Placing and Second Admission.

Applications for admission

Applications have been made to the London Stock Exchange and Irish Stock Exchange for the VCT Placing Shares to be admitted to trading on AIM and the ESM. It is expected that First Admission will become effective and that dealings in the VCT Placing Shares will commence on 10 October 2017.

Applications have been made to the London Stock Exchange and Irish Stock Exchange for the Non-VCT Placing Shares to be admitted to trading on AIM and the ESM. It is expected that Second Admission will become effective and that dealings in the Non-VCT Placing Shares will commence on 11 October 2017.

Total voting rights

Following First Admission but prior to Second Admission, the Company's issued ordinary share capital will consist of 216,839,632 Ordinary Shares, with each Ordinary Share carrying the right to one vote. The Company does not, and will not at the time of First Admission, hold any Ordinary Shares in treasury. This figure of 216,839,632 Ordinary Shares may therefore be used by shareholders in the Company, between the dates of First Admission and Second Admission, as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules ("DTRs").

 Following Second Admission, the Company's issued share capital will consist of 274,817,283 Ordinary Shares, with each Ordinary Share carrying the right to one vote. The Company does not, and will not at the time of Second Admission, hold any Ordinary Shares in treasury. This figure of 274,817,283 Ordinary Shares may therefore be used by shareholders in the Company from Second Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the DTRs.

Enquiries: